Your search history is turned on.
Date: May 7, 2024 Jurisdictions: Alberta, British Columbia, Ontario
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9 Saskatoon, Saskatchewan, May 7, 2024 ZYUS Life Sciences Corporation (ZYUS or the Company) (TSXV: ZYUS) is pleased to announce that Brent Zettl, President and...
ZYUS ANNOUNCES COMPLETION OF ITS ANNUAL FILINGS Saskatoon, Saskatchewan, May 7, 2024 ZYUS Life Sciences Corporation (ZYUS or the Company) (TSXV: ZYUS) today announces that, further to the Companys press release dated April 29, 2024, the Companys audited annual financial statements, the related managements discussion and analysis...
1 Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, John Hyshka, Chief Financial Officer, Zyus Life Sciences Corporation, certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by referenc...
1 Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Brent Zettl, President and Chief Executive Officer, Zyus Life Sciences Corporation, certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorp...
ZYUS MD&A zyus.com FOR FURTHER INFORMATION PLEASE CONTACT: ZYUS Life Sciences Corporation 407 Downey Road, Suite 204 Saskatoon, Saskatchewan Canada S7N 4L8 [email protected] [email protected] www.zyus.com TRADING SYMBOL: TSX-V: ZYUS ZYUS LIFE SCIEN...
Date: May 7, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, HYSHKA, John, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable ...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
zyus.com TSX-V: ZYUS 2023 ANNUAL FINANCIAL STATEMENTS AND NOTES DECEMBER 31, 2023 KPMG LLP 500, 475 2nd Avenue South Saskatoon, SK S7K 1P4 Canada Tel 306-934-6200 Fax 306-934-6233 www.kpmg.ca INDEPENDENT AUDITORS REPORT To the Board of Directors of ZYUS Life Sciences Corporation. Opinion We have audited the consolidated fina...
Date: April 29, 2024 Jurisdictions: Alberta, British Columbia, Ontario
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ZYUS ANNOUNCES ANTICIPATED DELAY IN ITS ANNUAL FILINGS Saskatoon, Saskatchewan, April 29, 2024 ZYUS Life Sciences Corporation (ZYUS or the Company) (TSXV: ZYUS) today announces that, as a result of a delay by the Companys auditor, KPM...
Date: April 23, 2024 Jurisdictions: Alberta, British Columbia, Ontario
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management ZYUS Receives Patent from United States Patent and Trademark Office (USPTO) Supporting ZYUS Lead Drug Candidate SASKATOON, Saskatchewan April 23, 2024 -- ZYUS Life Sciences Corporation (the Company) (TSX-V: ZYUS), a Canadian-base...